Glaxosmithkline

Glaxosmithkline, a UK-based Pharmaceutical Preparation Manufacturing company, has demonstrated a commitment to reducing its carbon emissions.

For 2024, Glaxosmithkline reported total carbon emissions of approximately 8.95 billion kg CO2e. This includes Scope 1 emissions of 521 million kg CO2e, Scope 2 emissions (market-based) of 44 million kg CO2e, and Scope 3 emissions of 8.385 billion kg CO2e. In 2023, total emissions were approximately 9.63 billion kg CO2e, comprising Scope 1 emissions of 580 million kg CO2e, Scope 2 emissions (market-based) of 64 million kg CO2e, and Scope 3 emissions of 8.983 billion kg CO2e. In 2022, total emissions were approximately 9.71 billion kg CO2e, with Scope 1 emissions at 626 million kg CO2e, Scope 2 emissions (market-based) at 88 million kg CO2e, and Scope 3 emissions at 8.995 billion kg CO2e.

Glaxosmithkline has set ambitious climate commitments validated by the Science Based Targets initiative (SBTi). The company aims to achieve net-zero greenhouse gas emissions across its entire value chain by 2045, with a 90% absolute reduction in emissions from a 2020 baseline across all scopes, and neutralising all residual emissions.

Near-term SBTi targets include an 80% absolute reduction in Scope 1 and 2 GHG emissions by 2030 from a 2020 base year. Additionally, Glaxosmithkline commits to an 80% absolute reduction in Scope 3 GHG emissions from specific categories (purchased goods and services, fuel and energy-related activities, upstream transportation and distribution, waste generated in operations, business travel, employee commuting, use of sold products, and end-of-life treatment of sold products) within the same timeframe. The company also commits to an 80% reduction in Scope 1 and 2 GHG emissions by 2030 from a 2020 base year.

Further long-term SBTi targets, set against a 2020 base year, include a 90% absolute reduction in Scope 1 and 2 GHG emissions by 2045. A 90% absolute reduction in Scope 3 GHG emissions from specific categories (purchased goods and services, capital goods, fuel and energy-related activities, upstream transportation and distribution, waste generated in operations, business travel, employee commuting, use of sold products, end-of-life treatment of sold products, and investments) is also targeted by 2045.

Glaxosmithkline's near-term Scope 1 and 2 targets are classified as consistent with reductions required to keep warming to 1.5°C. The company also signed the Climate Pledge in August 2021.